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Summary The therapeutic use of leeches in medicine dates back to 50 b.c. and
was cited by ancient authors. The medicinal leech, Hirudo medicinalis, has been
used with increasing frequency during the past few years by reconstructive surgeons
to help salvage ischaemic tissues. We aim to summarise the anatomy, physiology, and
pharmacological mechanisms of action of leeches to provide reconstructive surgeons
with a theoretical basis for their use.
© 2004 The British Association of Oral and Maxillofacial Surgeons. Published by
Elsevier Ltd. All rights reserved.
Introduction
Blood letting and the therapeutic use of Hirudo
medicinalis dates back to ancient Egypt and the be-
ginnings of civilisation.1 The popularity of the an-
nelid has varied throughout the ages depending on
the incumbent beliefs of the medical hierarchy. In
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recent years leeches have enjoyed a renaissance in
the world of reconstructive microsurgery. The ﬁrst
reported modern day use of leeches for alleviat-
ing venous engorgement following ﬂap surgery was
published by Derganc and Zdravid in I960.2 Their
series of 20 pedicled ﬂaps reported that the use
of leeches assisted them to achieve a 70% com-
plete salvage rate. Since then, there have been
many case reports describing the successful use of
leeches to alleviate venous congestion. The sur-
vival of compromised, venous-congested tissues is0266-4356/$ — see front matter © 2004 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
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improved by early application of a leech.3—7 The
most common indications for leeches include the
salvage of compromised microvascular free-tissue
transfers,8,9 replanted digits,10 ears,11 lips,12,13
scalps,14 and nasal tips.15 Foucher reported in 1981
that 6 of 10 artery-only distal replantations of dig-
its survived with the aid of leeches, a signiﬁcant
improvement over treatment with systemic antico-
agulants alone.10 Further information on the use
of leeches in clinical practice, their complications,
and a suggested protocol for their use can be found
elsewhere.4
Anatomy of the leech
The leech belongs to the phylum Annelida, a group
that includes earthworms and several other mem-
bers. There are more than 700 species of leech, all
of which are carnivorous and move using suckers
Leeches are hermaphrodite and contain both male
and female sexual organs, but they have no abil-
ity to self-fertilise. H. medicinalis, endemic to the
swamp lands of south-east Asia and Europe, is the
most useful species medically,16 because of their
pend on a number of mechanical and chemical fac-
tors, including warmth, concentrations of sodium
and arginine on the skin, whether the leech is hun-
gry, and whether there is blood on the surface.19
A combination of these factors causes serotonin-
dependent stimulation of peripheral neurons in the
leech’s pharynx and stimulates feeding behaviour.20
The feeding behaviour of a leech, in addition to
blood, can also be stimulated by a glucose in saline
solution, l-arginine, and serotonin.21 Biting is usu-
ally at temperatures between 33◦ and 40 ◦C and
they rarely bite below 25 ◦C.22
While it is feeding the leech secretes a number
of active chemicals into the wound from unicellular
salivary ductules situated at the leading edge of the
jaw (Table 1). These facilitate prolonged bleeding
from the wound, and allow the leech adequate time
to acquire a full meal of blood uninhibited by clot-
ting. Secretions during a single feed can prevent in
vitro coagulation of up to 100ml of human blood.23
Bite of a leech is painless, although the presence
of a local anaesthetic in the secretion is debated,
and no such substance has yet been found. The re-
ported volume of blood in each meal varies widely,
















Tability to bite deeply and to cause prolonged bleed-
ing from the wound after they are detached. H.
medicinalis can reach up to 12 cm long, but is typ-
ically about a third of this size and weighs about
1—1.5 g before it feeds. It is composed of around
102 segments with 5 annuli in each segment except
at each tapered end where there are fewer annuli.
Its surface is covered by a thin distensible cuticle
and outer mucinous coating, which allows the leech
to expand when it has fed.
The narrower tapered end is its head and the
opposite larger disc-like end is its bottom. Suck-
ing devices are present at both ends. The poste-
rior end consists of a large muscular organ for at-
tachment and crawling. The anterior, smaller, and
more mobile end is the head. The bite is created
by three jaws, each containing 60—100 pairs of cut-
ting teeth, forming the characteristic Y-shaped tri-
radiate conformation 1mm in diameter and up to
1.5mm in depth.17,18 The leech has a simple inter-
nal anatomy, consisting of a straight tubular diges-
tive tract with diverticula.
Feeding
A potential host is identiﬁed by its movement and
production of heat, and sweat and blood are de-
tected by chemoreceptors on the leech’s anterior
sucker. Attachment and the start of feeding de-eported volume of passive bleeding after detach-
ent of the leech, and its duration, varies widely.
olumes range from 2 to 50ml, and passive bleed-
ng has been reported to continue from 1h up to
2 h after detachment. Conforti et al. in a porcine
odel of venous congestion, found that the mean
olume of blood in a meal was 2.4ml.
Ninety percent of passive bleeding occurred
ithin 5 h, and the mean loss al 4 h was 2.5ml.24 No
roteolytic enzymes have been identiﬁed in the gut
f H. medicinalis. The digestive tract is colonised
y several symbiotic bacteria, which are thought
o digest blood and to protect it from puriﬁca-
ion. Aeromonas hydrophila has been identiﬁed as
he predominant bacterium, and Serratia, Kleb-
iella and Pseudomonas have also been isolated.25
he beneﬁt of prophylactic antibiotics during treat-









Inhibition of the coagu-
lation cascade
Hirudin
Proteinase inhibitors Bdellin, eglin
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ment with leeches has been reported.26 Water is ex-
tracted from the blood meal and excreted through
17 pairs of ventrally located nephridia. The diges-
tive process lasts up to 3 months and the leech may
not require feeding for up to a year after a full blood
meal.27
Salivary secretions
The best known salivary product of the leech is
hirudin, one of the most potent natural anticoagu-
lants. Hirudin was ﬁrst isolated and named by Hay-
croft in 1884.28 Its chemical analysis was completed
in 1955, and it was identiﬁed as a 65 amino acid
polypeptide with speciﬁc activity as a direct in-
hibitor of thrombin.29 Hirudin has a low molecular
weight of 9000, and is a speciﬁc non-enzymatic in-
hibitor of thrombin. Thrombin has two main roles in
the coagulation process: it stimulates the release of
platelet activation factor (PAF) and is the enzyme
responsible for the universal ﬁnal step in the coagu-
lation cascade. In this step, ﬁbrinogen is converted
to ﬁbrin, which acts to stabilise clots by form-














platelet factor 4, which is released during the co-
agulation process. Unlike heparin, hirudin does not
interfere with biosynthesis of clotting factors, or af-
fect other enzyme pathways such as that of lipopro-
tein lipase. However, resistance has been reported
in laboratory animals after repeated exposures.
Toxicity, antigenicity, and anaphylaxis have been
described after the use of hirudins, although their
overall risk:beneﬁt ratio is favourable.32 Deriva-
tives of hirudin, including lepirudin and bivalirudin
have been produced and cloned using recombinant
technology. These have been tested in numerous
clinical trials of anticoagulation for acute coronary
syndromes, percutaneous coronary interventions,
and prophylaxis of deep vein thrombosis.33,34
Lepirudin is licensed in the UK for anticoagula-
tion in patients who have heparin-induced throm-
bocytopenia. Hirudin derivatives are also available
commercially as topical preparations for condi-
tions such as bruising, superﬁcial thrombophlebitis,
chilblains, and varicose veins. Hirudin itself does
not account fully for the prolonged bleeding that
occurs after leeches have taken a blood meal;
several other proteins have been isolated that






























cin by blocking substrate-binding groups, which
revents other molecules binding to its saturable
ites.30
In vitro studies have suggested that hirudin also
nhibits active Factor X (Fig. 1).31 As an anticoag-
lant, hirudin has speciﬁc advantages over heparin
n that it does not require antithrombin III for its ac-
ivity, and it is not affected by heparin-neutralising
igure 1 Effect of hirudin and heparin on the coagu-
ation cascade. Heparin inhibits the conversion of pro-
hrombin to thrombin and also inhibits the activity of
hrombin by anti-thrombin III (AT-III). Hirudin has a direct
nhibitory effect on thrombin, and may also have activity
gainst activated Factor X.yaluronidase is a beta-endoglucoronidase, which,
ogether with an unidentiﬁed collagenase, in-
reases overall tissue permeability and ensures
aximum penetration of the salivary secretions.35
histamine-like vasodilator acts synergistically to
ncrease regional blood ﬂow. The saliva of H.
edicinalis also contains various proteinase in-
ibitors, including bdellin (a plasmin inhibitor),
rypsin, and eglin (inhibitors of chymotrypsin and
lastase).36 The secretions of H. medicinalis also
nhibit platelet aggregation. Normally, when the
ndothelium is injured, platelets come into con-
act with subendothelial collagen, which triggers
ctivation of platelets, recruitment of additional
latelets, and secretion of vasoactive substances
hat start the coagulation cascade.37 The initial ac-
ivation of platelets is thought to be inhibited by
everal proteins found in the saliva of H. medic-
nalis, including calin and apyrase.38—40 Human
latelet aggregation, induced in vitro by ADP, is in-
ibited by the leech’s salivary secretions.41 Saratin
s a copy of a protein recently isolated from the
aliva of H. medicinalis which also has antiplatelet
ctivity. It is thought to act by binding to collagen,
nd inhibiting the interaction between von Wille-
rand factor and collagen under conditions of in-
reased shear (Fig. 2).42 Saratin therefore inhibits
dherence and adhesion of platelets to the vessel
all.
There has been much interest in saratin in vas-
ular surgery, where its topical application signiﬁ-
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Figure 2 (A) Interaction between platelets and collagen. Injury to the vessel wall exposes collagen, which causes
platelet adhesion dependent on platelet membrane receptors. After adhesion, prostaglandin synthesis is stimulated,
promoting release of contents of the cytoplasmic granules, including ADP, serotonin and several other factors. Serotonin
causes local vasoconstriction, while ADP triggers platelet aggregation, and formation of the platelet plug. (B and C)
The coagulation pathway is stimulated leading to formation of ﬁbrin, which stabilises the platelet plug.
cantly reduces complications of platelet adhesion,
intimal hyperplasia, luminal stenosis, and throm-
bosis in rat experimental models.43 Saratin has also
been studied in a canine model of prosthetic ac-
cess for dialysis, in which topical application signif-
icantly reduced intimal hyperplasia and the risk of
stenosis.44
Hirudo medicinalis: technical tips and
psychological issues
A suggested protocol for the general use of leeches
can be found elsewhere.4 The application of
leeches to intraoral ﬂaps is unique, and care must
be taken to facilitate successful attachment. The
leech’s propensity to migrate after attachment has
caused problems in the past. Obstruction of up-
per airways has been described after migration of
leeches to the hypopharynx where they became en-
gorged with blood, and haemoptysis has been re-
ported after migration to the bronchus.45 A sug-
gestion from an eminent maxillofacial surgeon to
get around this problem involves suturing of the
‘sucker pad’ (as opposed to the mouth end) to the
skin of the ﬂap once the leech starts feeding. This
seems to stop its migration it has been reported that
about half of all patients are counselled routinely
before leeches are applied, and information sheets
are available in a few units. The services of a clin-
ical psychologist are rarely available. Only a small
number of patients refuse to have leeches,3,4 per-
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haps because they are so unwell and fearful of los-
ing their ﬂap, that they are happy to accept these
measures as a last resort.
Hirudo medicinalis and free-tissue
transfers
Microvascular free-tissue transfer is now common.
Despite its high success rate, about 8—10% re-
quire re-exploration when the viability of the ﬂap
is threatened.46 Venous thrombosis is more com-
mon than arterial thrombosis.47 Various methods of
monitoring of the ﬂap are in use at present but we
are still searching for the ideal technique.48 It has
been shown in experimental ﬂaps that acute ve-
nous obstruction is more damaging than acute and
complete obstruction of the pedicle, where both
arterial and venous supplies are affected.49,50 In a
porcine latissimus dorsi model, venous occlusion led
to necrosis of 40% of muscle ﬁbres after 3 h, com-
pared with no necrosis after arterial occlusion.51
Histological studies have shown that venous ob-































increase in survival of ﬂaps that were treated with a
combination of leeches and hyperbaric oxygen (67%
survival) compared with leeching alone (25%).55 Hy-
perbaric oxygen alone was not an effective treat-
ment, resulting in only 1% of ﬂaps surviving.
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